-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Oral and Poster Abstracts

Saturday, December 5, 2020

Saturday | Sunday | Monday | top

7:00 AM-3:30 PM

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I
102. Regulation of Iron Metabolism: Poster I
112. Thalassemia and Globin Gene Regulation: Poster I
113. Hemoglobinopathies, Excluding Thalassemia—New Genetic Approaches to Sickle Cell Disease: Poster I
114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster I
201. Granulocytes, Monocytes, and Macrophages: Poster I
203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I
301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Poster I
311. Disorders of Platelet Number or Function: Poster I
321. Blood Coagulation and Fibrinolytic Factors: Poster I
322. Disorders of Coagulation or Fibrinolysis: Poster I
331. Pathophysiology of Thrombosis: Poster I
332. Anticoagulation and Antithrombotic Therapy: Poster I
401. Clinical Sciences in Transfusion Medicine: Poster I
501. Hematopoietic Stem and Progenitor Biology: Poster I
502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Poster I
503. Clonal Hematopoiesis: Aging and Inflammation: Poster I
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Poster I
508. Bone Marrow Failure: Poster I
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster I
603. Oncogenes and Tumor Suppressors: Poster I
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster I
612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster I
613. Acute Myeloid Leukemia: Clinical Studies: Poster I
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
621. Lymphoma—Genetic/Epigenetic Biology: Poster I
622. Lymphoma Biology—Non-Genetic Studies: Poster I
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster I
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
632. Chronic Myeloid Leukemia: Therapy: Poster I
634. Myeloproliferative Syndromes: Clinical: Poster I
635. Myeloproliferative Syndromes: Basic Science: Poster I
636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I
637. Myelodysplastic Syndromes—Clinical Studies: Poster I
641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I
642. CLL: Therapy, excluding Transplantation: Poster I
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I
703. Adoptive Immunotherapy: Poster I
704. Immunotherapies: Poster I
711. Cell Collection and Processing: Poster I
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I
731. Clinical Autologous Transplantation: Results: Poster I
732. Clinical Allogeneic Transplantation: Results: Poster I
801. Gene Editing, Therapy and Transfer: Poster I
802. Chemical Biology and Experimental Therapeutics: Poster I
803. Emerging Diagnostic Tools and Techniques: Poster I
901. Health Services Research—Non-Malignant Conditions: Poster I
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I
903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I
904. Outcomes Research—Non-Malignant Conditions: Poster I
905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I
906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster I

7:30 AM-9:00 AM

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Mechanisms and Regulation of Erythropoiesis
114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Hydroxyurea for Sickle Cell Disease: Treatment Benefits and Potential Reproductive Risks for Women
311. Disorders of Platelet Number or Function: Heparin-Induced Thrombocytopenia and Immune Thrombocytopenia
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel combination therapies in treatment of newly diagnosed AML
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Single Cell Profiling and Novel molecular Markers
622. Lymphoma Biology—Non-Genetic Studies: Mechanisms of Lymphomagenesis, Progression, and Response
624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in T/NK Cell Lymphoma
632. Chronic Myeloid Leukemia: Therapy— Building The Future CML
634. Myeloproliferative Syndromes: Clinical: New Therapies and JAKi-based Combinations for Myelofibrosis
651. Myeloma: Biology and Pathophysiology, excluding Therapy: From Smoldering Myeloma to Active Myeloma: Innovative Early Detection Approaches, Epigenetic, Genomic and Transcriptome Scenarios.
704. Immunotherapies: Beyond T to NK
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
732. Clinical Allogeneic Transplantation: Results I

9:30 AM-11:00 AM

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Mechanisms, Diagnosis and Treatment of Inherited
113. Hemoglobinopathies, Excluding Thalassemia—New Genetic Approaches to Sickle Cell Disease: Fetal Hemoglobin Regulation And Reticulocyte Maturation In Sickle Cell Disease
203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Pathogenesis and Immunotherapy
401 Basic Science and Clinical Practice in Blood Transfusion: COVID-19 Convalescent Plasma, Antigen Typing and the Prothrombin Complex II
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Aberrant Nuclear Architecture and Chromatin Remodeling
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel promising therapies for relapsed/refractory AML
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma Clinical Trials
642. CLL: Therapy, excluding Transplantation I
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities I
731. Clinical Autologous Transplantation: Autologous Transplantation: Still the Backbone of Modern Myeloma Therapies
904. Outcomes Research—Non-Malignant Conditions: Bleeding, Immune Thrombocytopenia, and Other Hematologic Disorders

12:00 PM-1:30 PM

112. Thalassemia and Globin Gene Regulation
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML
625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Approaches to Overcome Resistance
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma
711. Cell Collection and Processing
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities II
803. Emerging Diagnostic Tools and Techniques II
904. Outcomes Research - Non-Malignant Conditions: Venous Thromboembolism Associated with Cancer and/or COVID-19
905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Healthcare Disparities
906-Outcomes Research—Malignant Conditions (Myeloid Disease): Real World Management And Outcome

2:00 PM-3:30 PM

102. Regulation of Iron Metabolism
113. Hemoglobinopathies, Excluding Thalassemia—New Genetic Approaches to Sickle Cell Disease: New Insights Into Sickle Cell Disease Pathophysiology
322. Disorders of Coagulation or Fibrinolysis: Hemophilia: Genes, Joints, and PK
332. Anticoagulation and Antithrombotic Therapy: Novel Agents, Reversal Drugs and Indications
401 Basic Science and Clinical Practice in Blood Transfusion: COVID-19 Convalescent Plasma and Transfusion Immunology I
501. Hematopoietic Stem and Progenitor Biology: New Insights into the Molecular Regulation of Hematopoietic Stem Cells
508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases
612. Acute Lymphoblastic Leukemia: Clinical Studies: Innovative Chemotherapy and Immunotherapy Strategies in Frontline and Relapsed Disease
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: MRD and Novel molecular Markers
621. Lymphoma—Genetic/Epigenetic Biology: Genetic and epigenetic profiling of malignant lymphomas
636. Myelodysplastic Syndromes—Basic and Translational Studies
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Bispecific T Cell Engager Therapies and Novel Targeting Agents
732. Clinical Allogeneic Transplantation Results III
901. Health Services Research—Non-Malignant Conditions I
902. Health Services Research—Malignant Conditions (Lymphoid Disease) I

Sunday, December 6, 2020

Saturday | Sunday | Monday | top

7:00 AM-3:30 PM

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
102. Regulation of Iron Metabolism: Poster II
112. Thalassemia and Globin Gene Regulation: Poster II
113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster II
114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II
201. Granulocytes, Monocytes, and Macrophages: Poster II
203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster II
301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Poster II
311. Disorders of Platelet Number or Function: Poster II
321. Blood Coagulation and Fibrinolytic Factors: Poster II
322. Disorders of Coagulation or Fibrinolysis: Poster II
331. Pathophysiology of Thrombosis: Poster II
332. Anticoagulation and Antithrombotic Therapy: Poster II
401. Basic Science and Clinical Practice in Blood Transfusion: Poster II
501. Hematopoietic Stem and Progenitor Biology: Poster II
502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Poster II
503. Clonal Hematopoiesis: Aging and Inflammation: Poster II
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Poster II
508. Bone Marrow Failure: Poster II
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster II
603. Oncogenes and Tumor Suppressors: Poster II
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster II
612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II
613. Acute Myeloid Leukemia: Clinical Studies: Poster II
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster II
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
621. Lymphoma—Genetic/Epigenetic Biology: Poster II
622. Lymphoma Biology—Non-Genetic Studies: Poster II
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II
625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II
626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia: Therapy: Poster II
634. Myeloproliferative Syndromes: Clinical: Poster II
635. Myeloproliferative Syndromes: Basic Science: Poster II
636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
637. Myelodysplastic Syndromes—Clinical Studies: Poster II
641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II
642. CLL: Therapy, excluding Transplantation: Poster II
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster II
703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster II
704. Immunotherapies: Poster II
711. Cell Collection and Processing: Poster II
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster II
731. Clinical Autologous Transplantation: Results: Poster II
732. Clinical Allogeneic Transplantation: Results: Poster II
801. Gene Editing, Therapy and Transfer: Poster II
802. Chemical Biology and Experimental Therapeutics: Poster II
803. Emerging Diagnostic Tools and Techniques: Poster II
901. Health Services Research—Non-Malignant Conditions: Poster II
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster II
903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster II
904. Outcomes Research—Non-Malignant Conditions: Poster II
905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II
906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster II

9:30 AM-11:00 AM

203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hematologic Malignancies and COVID-19
301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry
502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Molecular regulation of cell fate and regeneration
613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Clinical studies in Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia
634. Myeloproliferative Syndromes: Clinical: Translational Science in MPN— Hitting the Mark
641. CLL: Biology and Pathophysiology, excluding Therapy: Treatment Resistance and Prognosis
722. Clinical Allogeneic Transplantation: Acute and Chronic GvHD, Immune Reconstitution: Phase I and II Trials
803. Emerging Diagnostic Tools and Techniques I
904. Outcomes Research - Non-Malignant Conditions: Sickle Cell Disease and Beta Thalassemia
905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Lymphoma

12:00 PM-1:30 PM

311. Disorders of Platelet Number or Function: Thrombotic Thrombocytopenic Purpura and Platelet Dysfunction
503. Clonal Hematopoiesis: Aging and Inflammation
613. Acute Myeloid Leukemia: Molecular Mutations and Their Prognostic Implications
618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis II
626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Updates and advances in bispecific antibody therapies and autologous CAR-T approaches
636. Myelodysplastic Syndromes — Basic and Translational Studies
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Relapsed/Refractory Multiple Myeloma
722. Clinical Allogeneic Transplantation: Acute and Chronic GvHD, Immune Reconstitution: Pathobiology and Predictive Biomarkers
901. Health Services Research—Non-Malignant Conditions II
903. Health Services Research—Malignant Conditions (Myeloid Disease): Barriers to Cancer Care Delivery in Myeloid Malignancies
905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Myeloma

2:00 PM-3:30 PM

331. Pathophysiology of Thrombosis I
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Altered Transcription Factor Regulation
613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Targeted Therapies
624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: PCNSL Treatment and Prognosis and CNS Prophylaxis in High-Risk Aggressive Lymphomas
634. Myeloproliferative Syndromes: Clinical: Clinical Trials in Polycythemia Vera
651. Myeloma: Biology and Pathophysiology, excluding Therapy: The Role of the Bone Marrow Microenvironment in the Pathogenesis and Therapy of Multiple Myeloma and Waldenstrom’s Macroglobulinemia.
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence II
801. Gene Editing, Therapy and Transfer I

Monday, December 7, 2020

Saturday | Sunday | Monday | top

7:00 AM-8:30 AM

114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Assessment and Prevention of End-Organ Injury in Sickle Cell Disease
322. Disorders of Coagulation or Fibrinolysis: Hemophilia: Treatment and Inhibitors
331. Pathophysiology of Thrombosis II
603. Oncogenes and Tumor suppressors: Pre clinical models and Novel Targets
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Molecular pharmacology and drug resistance mechanisms in lymphoproliferative disorders
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Biomarkers and Prognostication in Aggressive B-Cell Non-Hodgkin Lymphomas
637. Myelodysplastic Syndromes—Clinical Studies: Personalized Clinical-Decision Tools and treatment of lower risk MDS
642. CLL: Therapy, excluding Transplantation II
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy
703. Adoptive Immunotherapy: Mechanisms and New Approaches: Optimizing CAR T cells for Improved Outcomes
732. Clinical Allogeneic Transplantation Results II
802. Chemical Biology and Experimental Therapeutics: Innovations in Therapy and Drug Screening

7:00 AM-3:30 PM

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III
102. Regulation of Iron Metabolism: Poster III
112. Thalassemia and Globin Gene Regulation: Poster III
113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III
114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster III
201. Granulocytes, Monocytes, and Macrophages: Poster III
203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III
301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Poster III
311. Disorders of Platelet Number or Function: Poster III
321. Blood Coagulation and Fibrinolytic Factors: Poster III
322. Disorders of Coagulation or Fibrinolysis: Poster III
331. Pathophysiology of Thrombosis: Poster III
332. Anticoagulation and Antithrombotic Therapy: Poster III
401. Basic Science and Clinical Practice in Blood Transfusion: Poster III
501. Hematopoietic Stem and Progenitor Biology: Poster III
502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Poster III
503. Clonal Hematopoiesis: Aging and Inflammation: Poster III
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Poster III
508. Bone Marrow Failure: Poster III
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III
603. Oncogenes and Tumor Suppressors: Poster III
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III
612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III
613. Acute Myeloid Leukemia: Clinical Studies: Poster III
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III
618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III
621. Lymphoma—Genetic/Epigenetic Biology: Poster III
622. Lymphoma Biology—Non-Genetic Studies: Poster III
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster III
626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Poster III
634. Myeloproliferative Syndromes: Clinical: Poster III
635. Myeloproliferative Syndromes: Basic Science: Poster III
636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
637. Myelodysplastic Syndromes—Clinical Studies: Poster III
641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
642. CLL: Therapy, excluding Transplantation: Poster III
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster III
703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster III
704. Immunotherapies: Poster III
711. Cell Collection and Processing: Poster III
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster III
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
731. Clinical Autologous Transplantation: Results: Poster III
732. Clinical Allogeneic Transplantation: Results: Poster III
801. Gene Editing, Therapy and Transfer: Poster III
802. Chemical Biology and Experimental Therapeutics: Poster III
803. Emerging Diagnostic Tools and Techniques: Poster III
901. Health Services Research—Non-Malignant Conditions: Poster III
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster III
903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III
904. Outcomes Research—Non-Malignant Conditions: Poster III
905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster III
906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster III

9:00 AM-10:30 AM

322. Disorders of Coagulation or Fibrinolysis: Von Willebrand Disease and Bleeding
332. Anticoagulation and Antithrombotic Therapy: COVID-19, Obesity and Hemorrhagic Complications
612. Acute Lymphoblastic Leukemia: Clinical Studies: Insights in Genomics, MRD, and Toxicities
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation I
622. Lymphoma Biology—Non-Genetic Studies: Microenvironment and Immune Response in Hodgkin Lymphoma
626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Incorporating novel agents and new adoptive cell therapy approaches
651. Myeloma: Biology and Pathophysiology, excluding Therapy I
703. Adoptive Immunotherapy: Mechanisms and New Approaches: Adoptive Cell Therapy beyond CAR T cells
731. Clinical Autologous Transplantation: Building Better Transplant Platforms in Lymphoid Malignancies
903. Health Services Research—Malignant Conditions (Myeloid Disease): Treatment and Publication Patterns in Myeloid Malignancies

11:30 AM-1:00 PM

321. Blood Coagulation and Fibrinolytic Factors: Coagulation and Fibrinolytic Factors: Regulation of Coagulation
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation II
621. Lymphoma—Genetic/Epigenetic Biology: Clinical implications of biological insights in lymphoma
624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy in T/NK Cell Lymphoma
632: Chronic Myeloid Leukemia: Therapy: CML: New and Beyond
637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes
641. CLL: Biology and Pathophysiology, excluding Therapy: Genetic Models and Genomic Landscape of CLL and Richter Transformation
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
801. Gene Editing, Therapy and Transfer II

1:30 PM-3:00 PM

114. Hemoglobinopathies, Excluding Thalassemia—Clinical:Novel Treatments for Sickle Cell Disease
201. Granulocytes, Monocytes, and Macrophages
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches
618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I
623. Mantle Cell and Indolent B-Cell Lymphoma - CAR-T and immunotherapy clinical studies
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Front-Line Treatment and Prognostication of Burkitt Lymphoma, Plasmablastic Lymphoma, and DLBCL
631. CML: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Progression in CML
635. Myeloproliferative Syndromes: Basic Science
651. Myeloma: Biology and Pathophysiology, excluding Therapy II
653. Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models
704. Immunotherapies: Therapeutic T cell Manipulation
902. Health Services Research—Malignant Conditions (Lymphoid Disease) II